Posted by aabag on August 28, 2005, at 12:46:39
In reply to Re: phase III anxiety trial for Ocinaplon's on hold, posted by Tom Twilight on August 28, 2005, at 5:55:17
That's right, Tom. There are a number of GABA-A receptor subtypes, some of which are responsible for sediation, anxiolysis (reduction of anxiety), muscle coordination, and amnesia. Ocinaplon (selective GABA-A agonist) works on the receptor subtype which "governs" anxiolysis and muscle coordination. Furthermore, the dependence issue is not present, in the trials I've looked at. With the current crop of benzos, dependence, short-term memory loss, and sediation are problems, to varying degrees and with varying individuals (I should know). Ocinaplon's claim to fame would be as a pure anxiolytic.
poster:aabag
thread:546772
URL: http://www.dr-bob.org/babble/20050827/msgs/547617.html